Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1350 |
| Open | 0.1350 |
| Bid | 0.1350 x N/A |
| Ask | 0.1400 x N/A |
| Day's Range | 0.1350 - 0.1350 |
| 52 Week Range | 0.1000 - 0.2500 |
| Volume | |
| Avg. Volume | 15,803 |
| Market Cap | 9.427M |
| Beta (5Y Monthly) | -0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- News Direct
Rakovina Therapeutics receives government grant to accelerate novel cancer therapy program
Rakovina Therapeutics chief scientific officer Mads Daugaard joined Proactive's Steve Darling to share news the company is receiving research and development funding from the National Research Coun...
- GlobeNewswire
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to $122,865 in non-dilutive research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Funding will support Rakovina Therapeutics scientists in the development of assays and animal models for evaluation of the Company’s novel classes of DNA-
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates
VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend the expiry date of 11,414,750 common share purchase warrants (the “Warrants”) issued by the Company. The original term of the Warrants was two years and they currently expire on March 25, 2023. The Company proposes to extend the expiry date by up to 12 months (the “Warrant Extension”). No other terms o
